Articles published by Janux Therapeutics
![](https://mms.businesswire.com/media/20240807262367/en/2209922/22/Logo.jpg)
Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
August 07, 2024
From Janux Therapeutics
Via Business Wire
Tickers
JANX
![](https://mms.businesswire.com/media/20240722549490/en/2192426/22/Logo.jpg)
![](https://mms.businesswire.com/media/20240507878675/en/2122020/22/Logo.jpg)
Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
May 07, 2024
From Janux Therapeutics
Via Business Wire
Tickers
JANX
![](https://mms.businesswire.com/media/20240308492974/en/2060332/22/Logo.jpg)
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
March 08, 2024
From Janux Therapeutics
Via Business Wire
Tickers
JANX
![](https://mms.businesswire.com/media/20240228758808/en/1538478/5/janux-logo-web_page_01.jpg)
![](https://mms.businesswire.com/media/20240227489330/en/1538478/5/janux-logo-web_page_01.jpg)
Janux Therapeutics Announces Proposed Public Offering of Common Stock
February 27, 2024
From Janux Therapeutics
Via Business Wire
Tickers
JANX
![](https://mms.businesswire.com/media/20240226741043/en/1538478/5/janux-logo-web_page_01.jpg)
![](https://mms.businesswire.com/media/20240220601963/en/2038624/22/Logo.jpg)
![](https://mms.businesswire.com/media/20240108673937/en/1538478/5/janux-logo-web_page_01.jpg)
Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer
January 08, 2024
From Janux Therapeutics
Via Business Wire
Tickers
JANX
![](https://mms.businesswire.com/media/20231107781590/en/1538478/5/janux-logo-web_page_01.jpg)
Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
November 07, 2023
From Janux Therapeutics
Via Business Wire
Tickers
JANX
![](https://mms.businesswire.com/media/20230808095915/en/1862460/22/Janux_Logo.jpg)
Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
August 08, 2023
From Janux Therapeutics
Via Business Wire
Tickers
JANX
![](https://mms.businesswire.com/media/20230717647990/en/1842329/22/6c4a43c4-28b0-47dd-b4e6-a0e5d6c43d42.jpg)
![](https://mms.businesswire.com/media/20230605005059/en/1052726/5/janux-logo-web_page_01.jpg)
Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development
June 05, 2023
From Janux Therapeutics
Via Business Wire
Tickers
JANX
![](https://mms.businesswire.com/media/20230509006173/en/1788530/22/sitelogo_Janux_Logo_RGB_72.jpg)
Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
May 09, 2023
From Janux Therapeutics
Via Business Wire
Tickers
JANX
![](https://mms.businesswire.com/media/20230424005872/en/1772598/22/Logo.jpg)
![](https://mms.businesswire.com/media/20230420005890/en/1538478/5/janux-logo-web_page_01.jpg)
![](https://mms.businesswire.com/media/20230310005380/en/1735889/22/Picture1.jpg)
Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
March 10, 2023
From Janux Therapeutics
Via Business Wire
Tickers
JANX
![](https://mms.businesswire.com/media/20220602005202/en/1128238/5/janux-logo-web_page_01.jpg)
![](https://mms.businesswire.com/media/20220426005494/en/1128238/5/janux-logo-web_page_01.jpg)
![](https://mms.businesswire.com/media/20210719005117/en/1128238/5/janux-logo-web_page_01.jpg)
![](https://mms.businesswire.com/media/20210603005058/en/882440/5/janux-logo-web_page_01.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.